BACKGROUND: Obesity predisposes to left ventricular (LV) dysfunction and heart failure; however, the risk of these complications has not been assessed in patients with a normal body mass index (BMI) but increased body fat content (normal-weight obesity, NWO). We hypothesized that LV performance in NWO may be impaired and sought to investigate potential contributors to cardiac functional abnormalities. METHODS AND RESULTS: One hundred sixty-eight subjects (age, 38±7 years) with BMI <25kg/m(2) and no history of any disease affecting the myocardium were classified on the basis of body fat content into 2 groups: with NWO and without NWO. Echocardiographic indices of LV systolic and diastolic function, including myocardial velocities and deformation, serological fibrosis markers, indicators of proinflammatory activation, and metabolic control, were evaluated. Subjects with NWO demonstrated impaired LV systolic and diastolic function, increased fibrosis intensity (assessed by procollagen type I carboxy-terminal propeptide [PICP]), impaired insulin sensitivity, and increased proinflammatory activation as compared with individuals with normal body fat. The independent correlates of LV systolic and diastolic function variables were as follows: for strain, IL-18 (β=-0.17, P<0.006), C-reactive protein (β=-0.20, P<0.002) and abdominal fat deposit (β=-0.20, P<0.003); for tissue S velocity, PICP (β=-0.21, P<0.002) and abdominal fat deposit (β=-0.43, P<0.0001); for tissue E velocity, abdominal fat deposit (β=-0.30, P<0.0001), PICP (β=-0.31, P<0.0001) and homeostasis model assessment of insulin resistance index (HOMA IR; β=-0.20, P<0.002); and for E/e'-PICP, IL-18 (both β=0.18, P<0.01) and HOMA IR (β=0.16, P<0.04). CONCLUSIONS: In patients with NWO, subclinical disturbances of LV function are independently associated with the extent of abdominal fat deposit, profibrotic state (as reflected by circulating PICP), reduced insulin sensitivity, and proinflammatory activation.
BACKGROUND:Obesity predisposes to left ventricular (LV) dysfunction and heart failure; however, the risk of these complications has not been assessed in patients with a normal body mass index (BMI) but increased body fat content (normal-weight obesity, NWO). We hypothesized that LV performance in NWO may be impaired and sought to investigate potential contributors to cardiac functional abnormalities. METHODS AND RESULTS: One hundred sixty-eight subjects (age, 38±7 years) with BMI <25kg/m(2) and no history of any disease affecting the myocardium were classified on the basis of body fat content into 2 groups: with NWO and without NWO. Echocardiographic indices of LV systolic and diastolic function, including myocardial velocities and deformation, serological fibrosis markers, indicators of proinflammatory activation, and metabolic control, were evaluated. Subjects with NWO demonstrated impaired LV systolic and diastolic function, increased fibrosis intensity (assessed by procollagen type I carboxy-terminal propeptide [PICP]), impaired insulin sensitivity, and increased proinflammatory activation as compared with individuals with normal body fat. The independent correlates of LV systolic and diastolic function variables were as follows: for strain, IL-18 (β=-0.17, P<0.006), C-reactive protein (β=-0.20, P<0.002) and abdominal fat deposit (β=-0.20, P<0.003); for tissue S velocity, PICP (β=-0.21, P<0.002) and abdominal fat deposit (β=-0.43, P<0.0001); for tissue E velocity, abdominal fat deposit (β=-0.30, P<0.0001), PICP (β=-0.31, P<0.0001) and homeostasis model assessment of insulin resistance index (HOMA IR; β=-0.20, P<0.002); and for E/e'-PICP, IL-18 (both β=0.18, P<0.01) and HOMA IR (β=0.16, P<0.04). CONCLUSIONS: In patients with NWO, subclinical disturbances of LV function are independently associated with the extent of abdominal fat deposit, profibrotic state (as reflected by circulating PICP), reduced insulin sensitivity, and proinflammatory activation.
Authors: Cesare Russo; Fusako Sera; Zhezhen Jin; Vittorio Palmieri; Shunichi Homma; Tatjana Rundek; Mitchell S V Elkind; Ralph L Sacco; Marco R Di Tullio Journal: Eur J Heart Fail Date: 2016-04-24 Impact factor: 15.534
Authors: XuanJi Li; Christopher Rensing; William L Taylor; Caitlin Costelle; Asker Daniel Brejnrod; Robert J Ferry; Paul B Higgins; Franco Folli; Kameswara Rao Kottapalli; Gene B Hubbard; Edward J Dick; Shibu Yooseph; Karen E Nelson; Natalia Schlabritz-Loutsevitch Journal: J Med Primatol Date: 2018-07-24 Impact factor: 0.667
Authors: N Schlabritz-Loutsevitch; K Apostolakis-Kyrus; R Krutilina; G Hubbard; M Kocak; Z Janjetovic; S Sathanandam; A T Slominski; G Mari; E Dick Journal: J Med Primatol Date: 2016-09-15 Impact factor: 0.667
Authors: Nir Ayalon; Deepa M Gopal; Deirdre M Mooney; Juliana S Simonetti; Jason R Grossman; Aeshita Dwivedi; Courtney Donohue; Alejandro J Perez; Jill Downing; Noyan Gokce; Edward J Miller; Chang-Seng Liang; Caroline M Apovian; Wilson S Colucci; Jennifer E Ho Journal: Am J Cardiol Date: 2014-07-01 Impact factor: 2.778
Authors: G Youcef; A Olivier; N Nicot; A Muller; C Deng; C Labat; R Fay; R-M Rodriguez-Guéant; C Leroy; F Jaisser; F Zannad; P Lacolley; L Vallar; A Pizard Journal: Br J Pharmacol Date: 2016-04-26 Impact factor: 8.739
Authors: Ravi V Shah; Siddique A Abbasi; Bobak Heydari; Carsten Rickers; David R Jacobs; Lu Wang; Raymond Y Kwong; David A Bluemke; Joao A C Lima; Michael Jerosch-Herold Journal: J Am Coll Cardiol Date: 2013-04-23 Impact factor: 24.094
Authors: Antonino De Lorenzo; Laura Soldati; Francesca Sarlo; Menotti Calvani; Nicola Di Lorenzo; Laura Di Renzo Journal: World J Gastroenterol Date: 2016-01-14 Impact factor: 5.742